Milestone Pharmaceuticals, Inc.

The disruption of existing markets is a dominant ambition of the nearly 20 applications expecting US Food and Drug Administration action in March. The Pink Sheet ’s US FDA Performance Tracker shows

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

Milestone Pharmaceuticals, Inc. ’s inhaled calcium channel blocker etripamil already has shown that it can significantly slow patients’ heart rates in a large Phase III clinical trial as a treatment f

Acesion Pharma ApS is on a mission to out-license its lead atrial fibrillation (AF) program for the acute setting after success in a Phase II proof-of-concept trial, a move that would enable the firm